Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Lung Neoplasms 8Neoplasm Metastasis 4Neoplasms 3Melanoma 2Colorectal Neoplasms 2Breast Neoplasms 2Thymoma 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Disease Progression 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Biliary Tract Neoplasms 1Advanced Non Small Cell Lung Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 6Nivolumab 3Gemcitabine 3Cisplatin 3Carboplatin 3brigimadlin 2Ramucirumab 2Fluorouracil 2Docetaxel 2Cetuximab 2tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trametinib 1regorafenib 1pertuzumab 1milademetan 1larotrectinib 1futibatinib 1durvalumab 1cemiplimab 1adagrasib 1Trastuzumab 1TAS-116 1Ritonavir 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Omacor 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × AZD 6244 × Thoracic × Clear all
NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
58 enrolled
BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡